Skip to main content
. 2013 Sep 16;122(19):3365–3375. doi: 10.1182/blood-2013-06-510586

Figure 4.

Figure 4

Association of the miRNA signature with aGVHD severity. (A) Expression levels of miR-423, miR-199a-3p, miR-93*, miR-377, miR-155, and miR-30a in aGVHD patients with different grades of disease (grade 1-2 vs grade 3-4). P values were calculated using the Mann-Whitney test. *P < .05; **P < .01; ***P < .001. (B) The kinetic expression of the miRNA signature in a set of 9 patients before disease onset (2 weeks after HCT) and after onset (6 weeks after HCT). We selected 9 aGVHD patients in the analysis according to the following criteria: they had similar diagnosis time (median day 20, range: 18 to 23) and didn’t develop aGVHD 2 weeks after HCT but had symptoms 6 weeks after HCT. P values were calculated using paired t tests.